Capricor Stock Soars, Shkreli Is Short: Here's What Pharma Bro Had To Say - Capricor Therapeutics (NASDAQ:CAPR)

Capricor Stock Soars, Shkreli Is Short: Here's What Pharma Bro Had To Say - Capricor Therapeutics (NASDAQ:CAPR)

Capricor Therapeutics, Inc. (NASDAQ:CAPR) stock soared on Wednesday after the company announced positive topline data from the Phase 3 HOPE-3 trial for its lead cell therapy candidate, deramiocel.  CAPR stock is soaring. See the real-time price action here.  The data release and stock surge triggered a dramatic response from controversial former pharma executive and prominent short-seller Martin Shkreli, who had publicly bet against Capricor's …

Capricor Therapeutics: Shares Soaring After DMD Study Win - Ball Now In FDA's Court (CAPR)

Capricor Therapeutics, Inc. soars 450% on positive HOPE-3 DMD results. Discover market impact, growth potential, and risks. Click for more on CAPR stock prospects.

Capricor says its cell therapy improved heart and muscle function in Duchenne patients

The outcome in the latest Phase 3 study will likely bolster the treatment’s regulatory future with the Food and Drug Administration.

Capricor soars on positive results for Duchenne cell therapy

Shares quadrupled now that the company appears on track to reverse an earlier FDA rejection of what could be the first treatment for heart-related complications of Duchenne.

Capricor stock soars after pivotal DMD cell therapy trial meets endpoints

Capricor’s trial enrolled both ambulatory and non-ambulatory DMD patients.The post Capricor stock soars after pivotal DMD cell therapy trial meets endpoints appeared first on Clinical Trials Arena.

Breakthrough Data Propels Capricor's Duchenne Therapy

Capricor Therapeutics has experienced a significant turnaround, with its stock price quadrupling following the release of impressive results from the Phase 3 Hope-3 clinical trial for its experimental cell therapy, deramiocel, designed to treat Duchenne muscular dystrophy (DMD). This trial success is crucial as it directly addresses the FDA’s earlier rejection of the drug, which had requested more substantial data. The new findings confirmed tha…